Graves Adrienne L 4

What Happened

• Adrienne L. Graves, a director of Ocular Therapeutix, was granted equity awards on June 10, 2026: 14,000 shares (RSUs) and an additional 44,000 derivative share awards, for a total of 58,000 RSU-type units. Each was recorded at $0.00 per share (typical for restricted stock units), so the grant price shown is $0.00 and no cash changed hands at grant.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
• Reported acquisition: 14,000 RSUs (explicitly described in footnote F1) and 44,000 derivative awards (listed as acquired at $0.00).
• Grant price/value: $0.00 per share on the Form 4 (RSUs are not purchases).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: F1 explains the 14,000 RSUs (each RSU equals one share) and F1/F2 describe that awards vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting (vesting is conditioned on continued board service).
• Filing timeliness: filed within two business days — not marked late.

Context

• These are restricted stock units (derivative awards) that convert to actual shares only upon vesting; they are compensation, not an open‑market purchase or sale. Grants to directors are a common form of compensation and do not necessarily indicate immediate buying or selling intent.